-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's drug marketing license application for injectable Ruikang Luzetolutamab (SHR-A2009 for injections) was accepted by the State Drug Administration.

Zhitongcaijing·07/29/2026 10:01:23
Listen to the news
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's drug marketing license application for injectable Ruikang Luzetolutamab (SHR-A2009 for injections) was accepted by the State Drug Administration.